US research roundup: Bright Minds Biosciences, Marvell Technology, Oracle
MRVL•Analysts cut Marvell Technology ratings and price targets, including BofA Global Research's downgrade to neutral from buy and target reduction to $225 from $400. Stephens raised Oracle to overweight from equal weight and increased its target to $213 from $185.
1. Analyst changes
Wall Street analysts revised ratings and price targets on several U.S.-listed companies. For Marvell Technology, BofA Global Research cut its rating to neutral from buy and lowered its price target to $225 from $400; TD Cowen cut its rating to hold from buy and target to $175 from $350. Melius Research, Needham, RBC and Wells Fargo also reduced Marvell price targets.
2. Other notable moves
Stephens raised Oracle to overweight from equal weight and increased its target price to $213 from $185. Bright Minds Biosciences received three target cuts: Baird lowered its target to $107 from $126, BTIG to $37 from $147, and Piper Sandler to $115 from $220. Tempus AI had several target increases, while Jefferies raised its rating to hold from underperform.
